To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using liter...To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases, a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg's and Egger's tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs, which involving 1,433 participants, were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23, 95% confidence interval (CI): 1.17, 1.29, P < 0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18, 95%CI: 1.06, 1.30, P=0.001]. Additionally, DS could also further reduce the content of fibrinogen, adjust blood lipid level, correct T wave inversion, and so on. Fifteen adverse drug reactions were reported in two studies, Four of which appeared in the experimental group. Based on the systematic review, the combined use of DS and WM was more effective than WM alone, it can be further widely used in clinic, however, there was no exact conclusion for its safety.展开更多
Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant r...Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant randomized controlled trials （RCTs） with meta-analysis. Methods： RCTs concerning AP treated by GD were searched in China Biology Medicine Disc （SinoMed）, PubMed, the China National Knowledge Infrastructure Database （CNKI）, the Chinese Scientific Journals Database （VIP）, Wanfang Database, Embase, and the Cochrane Library, from inception to February, 2017. The Cochrane Risk Assessment Tool was adopted to assess the methodological quality of the RCTs. The Review Manager 5.3 software was utilized to conduct the meta-analysis. Results： A total of 41 RCTs involving 4,462 patients were included in the meta-analysis. The results indicated that the combined use of GD and Western medicine （WM） against AP was associated with a higher total effective rate [risk ratio （RR）=1.25, 95% confidence interval （CI）： 1.21-1.29, P〈0.01], total effective rate of electrocardiogram （RR=1.29, 95% CI： 1.21-1.36, P〈0.01）. Additional, GD combined with WM could decrease the level of plasma viscosity [mean difference （MD）=-0.56, 95% CI： -0,81 to -0.30, P〈0.01], flbrinogen [MD=-1.02, 95% CI： -1.50 to -0.54, P〈0.01], whole blood low shear viscosity [MD=-2.27, 95% CI： -3.04 to -1.49, P〈0.01], and whole blood high shear viscosity （MD=-0.90, 95% CI： 1.37 to -0.44, P〈0.01）. Conclusions： Comparing with receiving WM only, the combine use of GD and WM was associated with a better curative effect for patients with AP. Nevertheless, limited by the methodological quality of included RCTs more large-sample, multi-center RCTs were needed to confirm our findings and provide further evidence for the clinical utility of GD.展开更多
Objectives:To investigate the effectiveness and safety of Xingnaojing Injection(XNJ,醒脑静注射液)compared with naloxone for the treatment of acute alcohol intoxication(AAI),and provide the latest evidence through evid...Objectives:To investigate the effectiveness and safety of Xingnaojing Injection(XNJ,醒脑静注射液)compared with naloxone for the treatment of acute alcohol intoxication(AAI),and provide the latest evidence through evidence-based approach.Methods:Seven electro-databases including Pub Med,EMBASE,Cochrane Central Register of Controlled Trials,Chinese National Knowledge Infrastructure Databases,Chinese Biomedical Literature Database,Chinese Science and Technology Periodical Database(VIP)and Wanfang Database were searched from the inception to January 2018.Randomized controlled trials(RCTs)comparing XNJ with naloxone for patients with AAI and reporting at least one of the below outcomes were included:patients’conscious recovery time,stay length in emergency department,disappearance time of the ataxia symptom,the severity of the symptoms,the blood alcohol content as wel as the adverse events.Methodological quality of included trials was assessed using the risk of bias tool which recommended by the Cochrane Col aboration.Meta-analysis was conducted by Review Manager 5.3 software.Results:Total y 141 trials with 13,901 patients were included in this review,al of them were assessed as unclear or high risk of bias.Results showed that on the basis of routine therapy,standard dose XNJ(10–20 m L)may have similar results with naloxone on the recovery time of consciousness(MD 12 min,95%CI 7.2–17.4 min)and disappearance time of symptoms(MD 6 min,95%CI–13.8–25.8 min)for patients with AAI.Larger dose of XNJ Injection(21–40 m L)may speed up the time(almost 1 h earlier).Combination of XNJ and naloxone seemed superior to the naloxone alone for al the relevant outcomes.The average difference of time in consciousness recovery was 2 h and the number of AAI patients whose consciousness recovery within 1 h was above 50%the combination group than in the control group(RR 1.42,95%CI 1.29 to 1.56).No severe adverse events or adverse reactions of XNJ were reported in the included trials.Conclusions:Low quality of evidence showed XNJ may have equal effect as naloxone and may achieve better effect as add-on intervention with naloxone for patients with AAI.We failed to evaluate the safety of XNJ Injection due to the insufficient evidence in this review.展开更多
Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin i...Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction,protein-protein interaction(PPI)data collection,network construction,network analysis,and enrichment analysis.Furthermore,molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.Results:Two networks were established,including a disease-target network and a PPI network of scutellarin targets against AP and IS.Network analysis showed that 14 targets,namely,AKT1,VEGFA,JUN,ALB,MTOR,ESR1,MAPK8,HSP90 AA1,NOS3,SERPINE1,FGA,F2,FOXO3,and STAT1,might be the therapeutic targets of scutellarin in AP and IS.Among them,NOS3 and F2 were recognized as the core targets.Additionally,molecular docking simulation confirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2.Furthermore,enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways,such as coagulation cascades,mitogen-activated protein kinase(MAPK)signaling pathway,phosphatidylinositol 3 kinase(PI3 K)/protein kinase B(Akt)/mammalian target of rapamycin(m TOR)signaling pathway,Toll-like receptor signaling pathway,hypoxia inducible factor-1(HIF-1)signaling pathway,forkhead box O(Fox O)signaling pathway,tumor necrosis factor(TNF)signaling pathway,adipocytokine signaling pathway,insulin signaling pathway,insulin resistance,and estrogen signaling pathway.Conclusions:The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant,anticoagulant,anti-inflammatory,and antioxidative effects as well as its effect on improving lipid metabolism.展开更多
Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized contro...Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.展开更多
基金Supported by the National Natural Science Foundation of China(No.81473547)Scientific Research Innovation Team Project of Beijing University of Chinese Medicine,China(No.2011-CXTD-14)
文摘To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases, a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg's and Egger's tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs, which involving 1,433 participants, were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23, 95% confidence interval (CI): 1.17, 1.29, P < 0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18, 95%CI: 1.06, 1.30, P=0.001]. Additionally, DS could also further reduce the content of fibrinogen, adjust blood lipid level, correct T wave inversion, and so on. Fifteen adverse drug reactions were reported in two studies, Four of which appeared in the experimental group. Based on the systematic review, the combined use of DS and WM was more effective than WM alone, it can be further widely used in clinic, however, there was no exact conclusion for its safety.
基金Supported by the National Natural Science Foundation of China(No.81473547 and No.81673829)
文摘Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant randomized controlled trials （RCTs） with meta-analysis. Methods： RCTs concerning AP treated by GD were searched in China Biology Medicine Disc （SinoMed）, PubMed, the China National Knowledge Infrastructure Database （CNKI）, the Chinese Scientific Journals Database （VIP）, Wanfang Database, Embase, and the Cochrane Library, from inception to February, 2017. The Cochrane Risk Assessment Tool was adopted to assess the methodological quality of the RCTs. The Review Manager 5.3 software was utilized to conduct the meta-analysis. Results： A total of 41 RCTs involving 4,462 patients were included in the meta-analysis. The results indicated that the combined use of GD and Western medicine （WM） against AP was associated with a higher total effective rate [risk ratio （RR）=1.25, 95% confidence interval （CI）： 1.21-1.29, P〈0.01], total effective rate of electrocardiogram （RR=1.29, 95% CI： 1.21-1.36, P〈0.01）. Additional, GD combined with WM could decrease the level of plasma viscosity [mean difference （MD）=-0.56, 95% CI： -0,81 to -0.30, P〈0.01], flbrinogen [MD=-1.02, 95% CI： -1.50 to -0.54, P〈0.01], whole blood low shear viscosity [MD=-2.27, 95% CI： -3.04 to -1.49, P〈0.01], and whole blood high shear viscosity （MD=-0.90, 95% CI： 1.37 to -0.44, P〈0.01）. Conclusions： Comparing with receiving WM only, the combine use of GD and WM was associated with a better curative effect for patients with AP. Nevertheless, limited by the methodological quality of included RCTs more large-sample, multi-center RCTs were needed to confirm our findings and provide further evidence for the clinical utility of GD.
基金Supported by the National Natural Science Foundation of China(No.81473547,81673829)the Beijing Municipal Organization Department Talents Project(No.2017000020124G292)
文摘Objectives:To investigate the effectiveness and safety of Xingnaojing Injection(XNJ,醒脑静注射液)compared with naloxone for the treatment of acute alcohol intoxication(AAI),and provide the latest evidence through evidence-based approach.Methods:Seven electro-databases including Pub Med,EMBASE,Cochrane Central Register of Controlled Trials,Chinese National Knowledge Infrastructure Databases,Chinese Biomedical Literature Database,Chinese Science and Technology Periodical Database(VIP)and Wanfang Database were searched from the inception to January 2018.Randomized controlled trials(RCTs)comparing XNJ with naloxone for patients with AAI and reporting at least one of the below outcomes were included:patients’conscious recovery time,stay length in emergency department,disappearance time of the ataxia symptom,the severity of the symptoms,the blood alcohol content as wel as the adverse events.Methodological quality of included trials was assessed using the risk of bias tool which recommended by the Cochrane Col aboration.Meta-analysis was conducted by Review Manager 5.3 software.Results:Total y 141 trials with 13,901 patients were included in this review,al of them were assessed as unclear or high risk of bias.Results showed that on the basis of routine therapy,standard dose XNJ(10–20 m L)may have similar results with naloxone on the recovery time of consciousness(MD 12 min,95%CI 7.2–17.4 min)and disappearance time of symptoms(MD 6 min,95%CI–13.8–25.8 min)for patients with AAI.Larger dose of XNJ Injection(21–40 m L)may speed up the time(almost 1 h earlier).Combination of XNJ and naloxone seemed superior to the naloxone alone for al the relevant outcomes.The average difference of time in consciousness recovery was 2 h and the number of AAI patients whose consciousness recovery within 1 h was above 50%the combination group than in the control group(RR 1.42,95%CI 1.29 to 1.56).No severe adverse events or adverse reactions of XNJ were reported in the included trials.Conclusions:Low quality of evidence showed XNJ may have equal effect as naloxone and may achieve better effect as add-on intervention with naloxone for patients with AAI.We failed to evaluate the safety of XNJ Injection due to the insufficient evidence in this review.
基金Supported by the National Natural Science Foundation of China(No.81473547,No.81673829)Young Scientists Training Program of Beijing University of Chinese Medicine(No.BUCM-YSTP-2019001)Cooperation Project of Beijing University of Chinese Medicine and Kunming Longjin Pharmaceutical(No.BUCM-YNLJ-2018001)。
文摘Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction,protein-protein interaction(PPI)data collection,network construction,network analysis,and enrichment analysis.Furthermore,molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.Results:Two networks were established,including a disease-target network and a PPI network of scutellarin targets against AP and IS.Network analysis showed that 14 targets,namely,AKT1,VEGFA,JUN,ALB,MTOR,ESR1,MAPK8,HSP90 AA1,NOS3,SERPINE1,FGA,F2,FOXO3,and STAT1,might be the therapeutic targets of scutellarin in AP and IS.Among them,NOS3 and F2 were recognized as the core targets.Additionally,molecular docking simulation confirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2.Furthermore,enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways,such as coagulation cascades,mitogen-activated protein kinase(MAPK)signaling pathway,phosphatidylinositol 3 kinase(PI3 K)/protein kinase B(Akt)/mammalian target of rapamycin(m TOR)signaling pathway,Toll-like receptor signaling pathway,hypoxia inducible factor-1(HIF-1)signaling pathway,forkhead box O(Fox O)signaling pathway,tumor necrosis factor(TNF)signaling pathway,adipocytokine signaling pathway,insulin signaling pathway,insulin resistance,and estrogen signaling pathway.Conclusions:The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant,anticoagulant,anti-inflammatory,and antioxidative effects as well as its effect on improving lipid metabolism.
基金Supported by the National Natural Science Foundation of China(No.81473547 and No.81673829)
文摘Objective： To systematically evaluate the effectiveness and safety of Sodium Tanshinone ⅡA Sulfonate Injection（STS） as one adjuvant therapy for treating unstable angina pectoris（UAP）. Methods： Randomized controlled trials（RCTs） of UAP treated by STS were searched in the China National Knowledge Infrastructure Database（CNKI）, VIP Database for Chinese Technical Periodicals（VIP）, Wanfang Database, the Chinese Biomedical Literature Database（CBM）, Web of Science, the Cochrane Library, Embase, and Pub Med, which from inception to January, 2016. The Cochrane Risk Assessment Tool was used to evaluate the methodological quality of the RCTs. The Review Manager 5.3 software was used to conduct the metaanalysis. Results： The results showed that 17 RCTs involving 1,372 patients were included. The meta-analysis indicated that the combined use of STS and Western medicine（WM） in the treatment of UAP can obviously improve the total effective rate [risk ratio（RR）=1.31, 95% confidence interval（CI）（1.24,1.39）, P〈0.0001], and the total effective rate of electrocardiogram [RR=1.43, 95% CI（1.30,1.56）, P〈0.0001], decrease the level of CRP [mean difference（MD）=–3.06, 95%CI（–3.85, –2.27）, P〈0.00001], fibrinogen [MD=–1.03, 95% CI（–1.16, –0.89）, P〈0.00001], and whole blood high shear viscosity [MD=–0.70, 95% CI（–0.92, –0.49）, P〈0.00001]. Additionally, the occurrence of adverse drug reaction of the experimental group was significantly higher than that of the control group [RR=3.57, 95% CI（1.28, 9.94）, P〈0.05]. Conclusions： Compared with WM, the combined use of STS was more effective.
